Multidisciplinary Strategies With Real-Time Fluorescence Images and Negative Pressure Wound Therapy to Manage Organ/Space Surgical Site Infection in Transplanted Kidneys
Chen, Chih-Heng MSa; Lee, Yi-Ching MSa; Wu, Yi-Chun MDb,c; Lee, Chi-Hung MDd; Tsai, Yuan-Jen MDe; Liu, Yung-Ching MDf; Chen, Yu-Han NPg; Wang, Fu-Yu RNg,h; Chang, Shun-Cheng MDg,i
aSchool of Medicine, College of Medicine, Taipei Medical University, Taipei bDivision of Plastic Surgery, Integrated Burn and Wound Care Center, Department of Surgery, Shuang-Ho Hospital, Taipei Medical University, New Taipei City cDepartment of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei dDivision of Infectious Diseases, Shuang-Ho Hospital, Taipei Medical University eShuang Ho Hospital, Taipei Medical University fDivision of Infectious Diseases, Department of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, New Taipei City gDivision of Plastic Surgery, Integrated Burn & Wound Care Center, Department of Surgery, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan hCabrini Hospital, Melbourne, Australia iDepartment of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Annals of Plastic Surgery 90(1):p S60-S67, April 2023.
Related Publications
Debridement/Wound Hygiene
Debridement/Wound Hygiene
Debridement/Wound Hygiene
Debridement/Wound Hygiene
Debridement/Wound Hygiene
MolecuLight Headquarters
425 University Avenue Suite 700 Toronto, ON M5G 1T6 Canada
US Address MolecuLight Corp. 2403 Sidney Street, Suite 286 Pittsburgh, PA 15203
T. 1-877-818-4360
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.